Reviewing Vaxcyte (NASDAQ:PCVX) and Kyverna Therapeutics (NASDAQ:KYTX)

Kyverna Therapeutics (NASDAQ:KYTX) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Profitability

This table compares Kyverna Therapeutics and Vaxcyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyverna Therapeutics	N/A	-51.12%	-37.91%
Vaxcyte	N/A	-23.53%	-22.20%

Institutional and Insider Ownership

18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 3.1% of Vaxcyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Kyverna Therapeutics and Vaxcyte, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyverna Therapeutics	0	1	7	1	3.00
Vaxcyte	0	0	7	0	3.00

Kyverna Therapeutics presently has a consensus target price of $25.71, indicating a potential upside of 448.28%. Vaxcyte has a consensus target price of $147.50, indicating a potential upside of 62.00%. Given Kyverna Therapeutics’ higher probable upside, research analysts plainly believe Kyverna Therapeutics is more favorable than Vaxcyte.

Valuation and Earnings

This table compares Kyverna Therapeutics and Vaxcyte”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyverna Therapeutics	$7.03 million	28.80	-$60.37 million	N/A	N/A
Vaxcyte	N/A	N/A	-$402.27 million	($4.60)	-19.79

Kyverna Therapeutics has higher revenue and earnings than Vaxcyte.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

About Vaxcyte

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.